ASH 2016 | The future of lymphoma treatment – combining new therapies with molecular diagnosis

Anna Sureda • 2 Dec 2016

ASH 2016

Anna Sureda, MD, PhD, from Duran I Reynals Hospital, Barcelona, Spain, discusses developments in lymphoma treatment at the American Society of Hematology (ASH) Congress 2016 in San Diego, CA. She explains that the presentation comparing the chemotherapy regimens R-CHOP with dose-adjusted (DA) EPOCH (NCT00118209) exemplifies what is happening in the lymphoma field. She argues that in future, the main goal is to significantly improve the long-term outcome of lymphoma patients, whether with more chemotherapy, different types of chemotherapy, a combination of chemotherapy with new drugs, or new drugs alone. She explains that what is still missing is an identification of the patient’s diagnostic group based on molecular signatures which are currently being used in prospective clinical trials. She concludes that combining these things will improve the clinical outcome of patients.